Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
DOP027: Efficacy and safety of an additional eight weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib eigth-week induction non-responders
Year: 2018
Source: ECCO'18 Vienna
Authors: Lukas Milan
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP027: Large scale drug screen reveals benzimidazole anti-helminthics as potential anti-TNF co-therapy
Year: 2016
Source: ECCO'16 DOP
Authors: Wildenberg M.
adalimumab, anti-TNF agents, Crohn's Disease, Ulcerative Colitis, infliximab, mucosal immunology
Files: 1
DOP027: Long-term efficacy and safety of ustekinumab in refractory Crohn’s Disease patients: A multicenter retrospective experience
Year: 2017
Source: ECCO'17 Barcelona
Authors: Wils P.
Crohn's disease, Anti-TNF agents, Ustekinumab
Files: 1
DOP028: 2nd N-ECCO consensus statements on the European nursing roles in caring for patients with Crohn’s Disease or Ulcerative Colitis
Year: 2018
Source: ECCO'18 Vienna
Authors: Kemp Karen
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP028: Antibodies towards vedolizumab appear from week 2 onwards and disappear upon treatment
Year: 2017
Source: ECCO'17 Barcelona
Authors: Bian S.
Anti drug antibodies, Vedolizumab, Immunology
Files: 1
DOP028: Efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohort
Year: 2016
Source: ECCO'16 DOP
Authors: Gecse K.
anti-TNF, biosimilars, infliximab
Files: 1
DOP029: Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: Post-hoc analysis of the taxit trial
Year: 2017
Source: ECCO'17 Barcelona
Authors: Van Stappen T.
Crohn's disease, Ulcerative colitis, Anti-TNF drug levels, Anti drug antibodies, Therapeutic drug monitoring, Infliximab
Files: 1
DOP029: Outcomes of a managed switching program changing IBD patients established on originator infliximab to biosimilar infliximab
Year: 2016
Source: ECCO'16 DOP
Authors: Cummings F.
anti-TNF, biosimilars, infliximab, real world data
Files: 1
DOP029: Treatment and long-term outcomes of paediatric patients with penetrating Crohn’s Disease
Year: 2018
Source: ECCO'18 Vienna
Authors: Pineton de Chambrun Guillaume
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP02: Supplementation with butyrate producing bacteria reduces tumor load in a mouse model of colitis associated cancer
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Ana Montalban-Arques
Created: Tuesday, 28 May 2019, 3:32 PM
Environmental factors, Microbiota, IBD-associated cancer, Colorectal cancer, IBD and malignancy, Microbiota
Files: 1
DOP02: The dose-dependent effect of enteral nutrition on faecal microbial metabolites of healthy volunteers
Year: 2020
Source: ECCO'20 Vienna
Authors: Vaios Svolos
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP030: Anti-TNF re-induction is as effective, simpler and cheaper compared with dose interval shortening following secondary loss of response in Crohn’s Disease: A dual centre ‘real world’ study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Srinivasan A.
Crohn's disease, Health economic analysis, Anti-TNF agents, Treat to target
Files: 1
DOP030: Elective switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study
Year: 2016
Source: ECCO'16 DOP
Authors: Smits L.
anti-TNF, biosimilars, infliximab, real world data
Files: 1
DOP030: The efficacy of home telemonitoring versus conventional follow-up: A randomised controlled trial among teenagers with Inflammatory Bowel Disease
Year: 2018
Source: ECCO'18 Vienna
Authors: Van Rheenen Patrick
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP031: Efficacy of infliximab biosimilar CT-P13 therapy on mucosal healing in ulcerative colitis – data from two Central European countries
Year: 2016
Source: ECCO'16 DOP
Authors: Bor R.
anti-TNF, biosimilars, infliximab, real world data, mucosal healing
Files: 1
DOP031: Individualized home-monitoring of disease activity in adult patients with Inflammatory Bowel Disease can be recommended implemented in clinical practice
Year: 2018
Source: ECCO'18 Vienna
Authors: Ankersen Dorit Vedel
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP031: Subtherapeutic serum infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab discontinuation in paediatric Crohn’s Disease patients
Year: 2017
Source: ECCO'17 Barcelona
Authors: Kang B.
Anti-TNF drug levels, Colonoscopy, Infliximab, Pharmacokinetics, Thiopurines (AZA / MP)
Files: 1
DOP032: 28Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe
Year: 2016
Source: ECCO'16 DOP
Authors: Kolar M.
anti-TNF, biosimilars, infliximab, real world data
Files: 1
DOP032: Crohn’s Disease patients’ perspectives towards de-escalating immunosuppressive therapy: A comparative French and American survey
Year: 2018
Source: ECCO'18 Vienna
Authors: Siegel Corey A.
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP032: Hydrocortisone premedication withdrawal in patients on stable infliximab maintenance: Clinical and pharmacokinetic outcomes
Year: 2017
Source: ECCO'17 Barcelona
Authors: Tran-Minh M.
Anti-TNF drug levels, Anti-drug antibodies, Anti-TNF agents, Infliximab
Files: 1